Frautschy, Sally, Ph.D.
  • Professor in Residence of Neurology, David Geffen School of Medicine at UCLA

  • Alzheimer Research Lab Professor, Dept of Medicine and Neurology at UCLA

Frautschy, Sally, Ph.D.

Contact

VA Greater Los Angeles Healthcare System
West Los Angeles Medical Center
11301 Wilshire Blvd., Building 113, Room #312
Los Angeles, CA 90073
Tel: (310) 478-3711 x46499
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Specialty

Alzheimer's Disease

Top

Biography

Dr. Frautschy focus in her graduate & initial post-graduate work was to understand the adverse effects of chronic stress on physiology, intrigued by the work of Hans Selye who in 1956 coined a word "stress" from physics to use to describe the physiological/chemical response to an emotional reaction. She worked under experts in the field of 'stress', completing her MS under the late Gary Moberg at UC Davis in 1980 and PhD in 1986 under Professor Robert Liptrap, DVM, PhD at Univ. of Guelph, Ontario Canada (also a photographer.) After completing her PhD, she trained with Dipak Sarkar (UCSD, now at Rutgers), another neuroendocrinogist. During her 2nd post doc with Dr. Andrew Baird & directorship of Roger Guillemin (a nobel laureate who did his post doc under Hans Selye), Sally worked on brain injury induction of neurotrophic factors where she bega her collaboration with Dr. Cole. Many neurotrophic factors become elevated in the Alzheimer brain as a 'response' to injury. In 1988, Dr. Frautschy, in collaboration with Dr. Cole, decided to evaluate the brain's response to human amyloid, and was the first to describe the inflammatory response. Since then, her priority has been to develop practical and effective approaches, particularly nutritional, for stopping this tragic disease, which in part, evolves from a personal experience with head injury.

Top

Publications

  • Ma QL, Yang F, Frautschy SA., Cole GMPAK in Alzheimer disease, Huntington disease and X-linked mental retardation. Cell Logist 2012;2(2):117-125. PMID: 23162743; PMCID: PMC3490962
  • Ma QL, Zuo X, Yang F, Ubeda O, Gant D, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA. Curcumin suppresses soluble tau oligomers and corrects molecular chaperone, synaptic and behavioral deficits in aged human tau transgenic mice. J Biol Chem 2012 Dec 21. PMID: 23264626
  • Roychaudhuri R, Yang M, Deshpande A, Cole GM, Frautschy S, Lomakin A, Benedek GB, Teplow DB. C-Terminal Turn Stability Determines Assembly Differences between Aβ40 and Aβ42. J Mol Biol 2013;425(2):292-308. doi: 10.1016/j.jmb.2012.11.006. PMID: 23154165
  • Frautschy SA, Cole GM. What was lost in translation in the DHA trial is whom you should intend to treat. Alzheimers Res Ther 2011 Jan 20;3(1):2. doi: 10.1186/alzrt61. PMID: 21251328; PMCID: PMC3109411
  • Cole GM, Frautschy SA. Why pleiotropic interventions are Needed for Alzheimer's disease. Mol Neurobiol. 2010 Jun;41(2-3):392-409.
  • Cole GM, Frautschy SA. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol Disord Drug Targets. 2010 Apr;9(2):140-148.
  • Cole GM, Frautschy SA. DHA may prevent age-related dementia. J Nutr. 2010;140(4):869-874.
  • Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, Cole GM. Reduction of SorLa/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer Disease Cerebrospinal Fluid.  Arch Neurol 2009 Apr;66(4):448-457.
  • Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim PC, Davies P, Ma Q, Cole GM, Frautschy SA. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 2009 Feb;33(2):193-206.
  • Begum AN, Yang F, Teng E, Hu S, Jones MR, Rosario ER, Beech W, Hudspeth B, Ubeda OJ, Cole GM, Frautschy SA. Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model. J Alzheimers Dis 2008 Dec;15(4):625-640.
  • Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull K, Teter B, Cole GM, Frautschy SA. Curcumin structure-function, bioavailablity and efficacy in models of neuroinflammation and Alzheimer’s.  J Pharmacol Exp Ther 2008 Jul;326(1):196-208.
  • Ma QL, Yang F, Calon F, Ubeda OJ, Hansen JE, Weisbart RH, Beech W, Frautschy SA, Cole GM.  P21-activated kinase aberrant activation and translocation in Alzheimer's disease pathogenesis. rrant activation and translocation in Alzheimer disease pathogenesis. J Biol Chem 2008 May 16;283(20):14132-14143.
  • Ma QL, Teter B, Ubeda OJ, Morihara T, Dhoot D, Nyby MD, Tuck ML, Frautschy SA, Cole GM.  Omega-3 Fatty Acid Docosahexaenoic Acid Increases Sorla/LR11, a Sorting Protein with Reduced Expression in Sporadic Alzheimer Disease (AD): Relevance to AD Prevention.  Journal of Neuroscience December 26, 2007;27(52):14299 –14307.

Top